Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk

It is unclear whether breast cancer risk varies by age and menopausal status in relation to use of hormonal birth control (HBC) and hormone replacement therapy (HRT), taken singly or cumulatively. The authors utilized data from 1,478 cases and 1,493 controls aged 20-98 years with known menopausal status, who had participated in a population-based, case-control study conducted on Long Island during 1996-1997. Exogenous hormone use over the lifecourse was assessed by use of memory aids. The authors examined associations among women in these subgroups: premenopausal (n = 968), postmenopausal <65 years (n = 1,045), and postmenopausal 65 years (n = 958). Among premenopausal women, risk was increased for ever use of HBC (odds ratio (OR) = 1.37, 95% confidence interval (CI): 1.04, 1.81) or HRT (OR = 1.81, 95% CI: 1.17, 2.81) and was pronounced among women reporting use of both HBC and HRT (OR = 2.59, 95% CI: 1.50, 4.46), long-term HRT use (OR = 3.93, 95% CI: 1.43, 10.84), or estrogen-plus-progestin therapy (OR = 3.51, 95% CI: 1.45, 8.49).

Saved in:
Bibliographic Details
Main Authors: Shantakumar, Sumitra, Therry, Mary Beth autor/a, Paykin, Andrea autor/a, Teitelbaum, Susan L. autor/a
Format: Texto biblioteca
Language:eng
Subjects:Terapia de reemplazo de hormonas, Cáncer de mama, Anticonceptivos orales, Menopausia,
Tags: Add Tag
No Tags, Be the first to tag this record!
id KOHA-OAI-ECOSUR:43648
record_format koha
spelling KOHA-OAI-ECOSUR:436482020-11-25T14:53:50ZAge and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk Shantakumar, Sumitra Therry, Mary Beth autor/a Paykin, Andrea autor/a Teitelbaum, Susan L. autor/a textengIt is unclear whether breast cancer risk varies by age and menopausal status in relation to use of hormonal birth control (HBC) and hormone replacement therapy (HRT), taken singly or cumulatively. The authors utilized data from 1,478 cases and 1,493 controls aged 20-98 years with known menopausal status, who had participated in a population-based, case-control study conducted on Long Island during 1996-1997. Exogenous hormone use over the lifecourse was assessed by use of memory aids. The authors examined associations among women in these subgroups: premenopausal (n = 968), postmenopausal <65 years (n = 1,045), and postmenopausal 65 years (n = 958). Among premenopausal women, risk was increased for ever use of HBC (odds ratio (OR) = 1.37, 95% confidence interval (CI): 1.04, 1.81) or HRT (OR = 1.81, 95% CI: 1.17, 2.81) and was pronounced among women reporting use of both HBC and HRT (OR = 2.59, 95% CI: 1.50, 4.46), long-term HRT use (OR = 3.93, 95% CI: 1.43, 10.84), or estrogen-plus-progestin therapy (OR = 3.51, 95% CI: 1.45, 8.49).There was no effect of ever HBC use among postmenopausal women aged less than 65 years, but risk was modestly elevated for more than 5 years of HRT use (OR = 1.41, 95% CI: 1.00, 1.99). Among postmenopausal women aged 65 years or more, odds ratios for HBC or HRT use were around the null. These results emphasize that timing of exogenous hormone use is important. Women who used these hormones before menopause had elevated risks, but the harmful effects began to decline with age after menopause.It is unclear whether breast cancer risk varies by age and menopausal status in relation to use of hormonal birth control (HBC) and hormone replacement therapy (HRT), taken singly or cumulatively. The authors utilized data from 1,478 cases and 1,493 controls aged 20-98 years with known menopausal status, who had participated in a population-based, case-control study conducted on Long Island during 1996-1997. Exogenous hormone use over the lifecourse was assessed by use of memory aids. The authors examined associations among women in these subgroups: premenopausal (n = 968), postmenopausal <65 years (n = 1,045), and postmenopausal 65 years (n = 958). Among premenopausal women, risk was increased for ever use of HBC (odds ratio (OR) = 1.37, 95% confidence interval (CI): 1.04, 1.81) or HRT (OR = 1.81, 95% CI: 1.17, 2.81) and was pronounced among women reporting use of both HBC and HRT (OR = 2.59, 95% CI: 1.50, 4.46), long-term HRT use (OR = 3.93, 95% CI: 1.43, 10.84), or estrogen-plus-progestin therapy (OR = 3.51, 95% CI: 1.45, 8.49).There was no effect of ever HBC use among postmenopausal women aged less than 65 years, but risk was modestly elevated for more than 5 years of HRT use (OR = 1.41, 95% CI: 1.00, 1.99). Among postmenopausal women aged 65 years or more, odds ratios for HBC or HRT use were around the null. These results emphasize that timing of exogenous hormone use is important. Women who used these hormones before menopause had elevated risks, but the harmful effects began to decline with age after menopause.Terapia de reemplazo de hormonasCáncer de mamaAnticonceptivos oralesMenopausiaAmerican Journal of Epidemiology
institution ECOSUR
collection Koha
country México
countrycode MX
component Bibliográfico
access En linea
databasecode cat-ecosur
tag biblioteca
region America del Norte
libraryname Sistema de Información Bibliotecario de ECOSUR (SIBE)
language eng
topic Terapia de reemplazo de hormonas
Cáncer de mama
Anticonceptivos orales
Menopausia
Terapia de reemplazo de hormonas
Cáncer de mama
Anticonceptivos orales
Menopausia
spellingShingle Terapia de reemplazo de hormonas
Cáncer de mama
Anticonceptivos orales
Menopausia
Terapia de reemplazo de hormonas
Cáncer de mama
Anticonceptivos orales
Menopausia
Shantakumar, Sumitra
Therry, Mary Beth autor/a
Paykin, Andrea autor/a
Teitelbaum, Susan L. autor/a
Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk
description It is unclear whether breast cancer risk varies by age and menopausal status in relation to use of hormonal birth control (HBC) and hormone replacement therapy (HRT), taken singly or cumulatively. The authors utilized data from 1,478 cases and 1,493 controls aged 20-98 years with known menopausal status, who had participated in a population-based, case-control study conducted on Long Island during 1996-1997. Exogenous hormone use over the lifecourse was assessed by use of memory aids. The authors examined associations among women in these subgroups: premenopausal (n = 968), postmenopausal <65 years (n = 1,045), and postmenopausal 65 years (n = 958). Among premenopausal women, risk was increased for ever use of HBC (odds ratio (OR) = 1.37, 95% confidence interval (CI): 1.04, 1.81) or HRT (OR = 1.81, 95% CI: 1.17, 2.81) and was pronounced among women reporting use of both HBC and HRT (OR = 2.59, 95% CI: 1.50, 4.46), long-term HRT use (OR = 3.93, 95% CI: 1.43, 10.84), or estrogen-plus-progestin therapy (OR = 3.51, 95% CI: 1.45, 8.49).
format Texto
topic_facet Terapia de reemplazo de hormonas
Cáncer de mama
Anticonceptivos orales
Menopausia
author Shantakumar, Sumitra
Therry, Mary Beth autor/a
Paykin, Andrea autor/a
Teitelbaum, Susan L. autor/a
author_facet Shantakumar, Sumitra
Therry, Mary Beth autor/a
Paykin, Andrea autor/a
Teitelbaum, Susan L. autor/a
author_sort Shantakumar, Sumitra
title Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk
title_short Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk
title_full Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk
title_fullStr Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk
title_full_unstemmed Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk
title_sort age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk
work_keys_str_mv AT shantakumarsumitra ageandmenopausaleffectsofhormonalbirthcontrolandhormonereplacementtherapyinrelationtobreastcancerrisk
AT therrymarybethautora ageandmenopausaleffectsofhormonalbirthcontrolandhormonereplacementtherapyinrelationtobreastcancerrisk
AT paykinandreaautora ageandmenopausaleffectsofhormonalbirthcontrolandhormonereplacementtherapyinrelationtobreastcancerrisk
AT teitelbaumsusanlautora ageandmenopausaleffectsofhormonalbirthcontrolandhormonereplacementtherapyinrelationtobreastcancerrisk
_version_ 1756226353145839617